The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
ORGANIZATION
EFPIA Japan Chief Frets Negative Market Growth amid Pressure on Drug Costs
Medium and long-term policies being weighed by the Japanese government to rein in drug spending would lead to negative growth in the country’s pharmaceutical market, EFPIA Japan Chairman Carsten Brunn warned on June 10. EFPIA Japan, formally the European Federation…
To read the full story
Related Article
- Japan Drug Costs to Remain Flat thru 2025, No Annual Price Cuts Necessary: EFPIA
April 15, 2015
- EFPIA Japan Chairman Says Drug Costs Won’t Explode
January 14, 2015
- EFPIA Japan Chairman Calls for More Rewards for Innovation
December 22, 2014
ORGANIZATION
- Trade Groups Hail Spillover Abolition, but Urge Further Overhauls
December 26, 2025
- EFPIA Japan, Patient Groups Call for Stronger Health Literacy, PPI
December 22, 2025
- JPMA Exec Renews Call for Simpler Drug Pricing System
December 19, 2025
- JGA to Create “Stable Supply Network” Membership to Expand Ramp-Up Scheme
December 18, 2025
- Pharma Groups Reiterate “No” to Broader CEA Use, Huge-Seller and Spillover Rules: Joint Statement
December 17, 2025
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Novartis’ Pluvicto (lutetium vipivotide tetraxetan (177Lu)) won reimbursement listing in Japan in November as a radioligand therapy (RLT) for PSMA-positive…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…